Immunocore Holdings plc (NasdaqGS: IMCR)
Health Care · Biotechnology · GB
$29.09
-1.09% today · -14.4% 1Y
Immunocore Holdings plc (NasdaqGS: IMCR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.50B and employs 524 people.
Over the last twelve months the share price has lost 14.4%, trading between 27.56 and 40.71.
Tweenvest scores Immunocore Holdings plc across four factors: quality 47/100, value 65/100, growth 100/100. Its strongest factor is growth.
IMCR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.50B
- Revenue (TTM)
- $430.77M
- P/E
- —
- EPS
- -0.36
- Dividend yield
- —
- Beta (5Y)
- 0.82
- 52-week high
- $40.71
- 52-week low
- $27.56
- Avg volume (3M)
- —
- Shares outstanding
- 51.50M
- Employees
- 524
- Next earnings
- —
About Immunocore Holdings plc
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.
- ISIN
- US45258D1054
- Founded
- 1999
- Listed since
- Feb 5, 2021
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Wedge Industrial Co.,Ltd.SZSE: 000534 | $1.56B | CN¥21.63 | -4.46% |
| Stoke Therapeutics, Inc.NasdaqGS: STOK | $1.55B | $23.95 | -1.40% |
| Absci CorporationNasdaqGS: ABSI | $1.53B | $8.94 | -3.04% |
| GenFleet Therapeutics (Shanghai) Inc.SEHK: 2595 | $1.51B | HK$31.94 | +6.82% |
| Ultragenyx Pharmaceutical Inc.NasdaqGS: RARE | $1.50B | $15.29 | +0.46% |
| Biotest GmbH & Co. KGaAHMSE: BIO0 | $1.48B | €33.20 | -0.60% |
| D&D Pharmatech Inc.KOSDAQ: A347850 | $1.46B | ₩43,000.00 | -3.37% |
| Staidson (Beijing) BioPharmaceuticals Co., Ltd.SZSE: 300204 | $1.46B | CN¥20.44 | +2.10% |
Figures last refreshed Oct 4, 2026.